Skip to main content

Home/ GAVNet Collaborative Curation/ Group items tagged R&D

Rss Feed Group items tagged

Steve Bosserman

How Instagram Saved Poetry - 0 views

  • In 2010, the editor of n+1 magazine, Chad Harbach, famously wrote that there were two distinct and rival literary cultures in America: the institutional, university-driven M.F.A. track and the New York–centered publishing world. But now there is a third option: the fast-paced, democratizing, hyper-connected culture of the internet. The poets of this third category often have little formal training, and their publishers are strewn across the country. Andrews McMeel, for instance, is an indie publisher in Missouri. Social media seem to have cracked the walls around a field that has long been seen as highbrow, exclusive, esoteric, and ruled by tradition, opening it up for young poets with broad appeal, many of whom are women and people of color.
  • Social-media poets, using Instagram as a marketing tool, are not just artists—they’re entrepreneurs. They still primarily earn money through publication and live events, but sharing their work on Instagram is now what opens up the possibility for both. Kaur, the ultimate poet-entrepreneur, said she approaches poetry like “running a business.” A day in the life can consist of all-day writing, touring, or, perhaps unprecedented for a poet, time in the office with her team to oversee operations and manage projects.
Bill Fulkerson

Trump's NAFTA Deal Simply Can't Solve America's Manufacturing Problems | naked capitalism - 0 views

  •  
    "As early as the 1980s, this insight was presciently confirmed by the late scholar Seymour Melman. Melman was one of the first to state the perhaps not-so-obvious fact that the huge amount of Department of Defense (DoD) Research and Development (R&D) pumped into the economy has actually stifled American civilian industry innovation and competitiveness, most notably in the very manufacturing sector that Trump is seeking to revitalize with these "reformed" trade deals."
Bill Fulkerson

Researchers publish striking images of SARS-CoV-2 infected cells - 0 views

  •  
    Ehre, a member of the UNC Marsico Lung Institute and the UNC Children's Research Institute, captured these images to illustrate how intense the SARS-CoV-2 infection of the airways can be in very graphic and easily understood images. Her lab conducted this research in collaboration with the labs of Ralph Baric, Ph.D., the William R. Kenan Distinguished Professor of Epidemiology at the UNC Gillings School of Public Health, who holds a joint faculty appointment at the UNC Department of Microbiology and Immunology, and Richard Boucher, MD, the James C. Moeser Eminent Distinguished Professor of Medicine and Director of the Marsico Lung Institute at the UNC School of Medicine Covid-19
Steve Bosserman

Biology Will Be the Next Great Computing Platform - 0 views

  • Crispr, the powerful gene-editing tool, is revolutionizing the speed and scope with which scientists can modify the DNA of organisms, including human cells. So many people want to use it—from academic researchers to agtech companies to biopharma firms—that new companies are popping up to staunch the demand. Companies like Synthego, which is using a combination of software engineering and hardware automation to become the Amazon of genome engineering. And Inscripta, which wants to be the Apple. And Twist Bioscience, which could be the Intel
  • “Being able to do that in a parallel way is the novel part,” says Paul Dabrowski, who estimates that Synthego cuts down the time it takes for a scientists to perform gene edits from several months to just one.
  • They’re betting biology will be the next great computing platform, DNA will be the code that runs it, and Crispr will be the programming language.
  • ...2 more annotations...
  • his company’s first move was to release a different gene-editing enzyme called MAD7—you can think of it like a Crispr/Cas9 knockoff, but legal—free for R&D uses. Inscripta will charge a single-digit royalty, far below market standards, to use MAD7 in manufacturing products or therapeutics.
  • We’re trying to get more people into the game now, by democratizing access to this family of enzymes,” he says. It’s a page from the Steve Jobs playbook; get them hooked on the MADzyme platform, down the line sell them personal hardware.
1 - 7 of 7
Showing 20 items per page